Qualification of LSP1-2111 as a brain penetrant group III metabotropic glutamate receptor orthosteric agonist

ACS Medicinal Chemistry Letters

Volumn 5, Issue 2, 2014, Pages 119-123

  Cajina, Manuel ^a   Nattini, Megan ^a   Song, Dekun ^a   Smagin, Gennady ^a   Jørgensen, Erling B ^b   Chandrasena, Gamini ^a   Bundgaard, Christoffer ^b   Toft, Dorthe Bach ^b   Huang, Xinyan ^a   Acher, Francine ^c   Doller, Dario ^a  

^a LUNDBECK RESEARCH USA   (United States)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

G protein coupled receptors; Metabotropic glutamate receptors; mGlu4 receptor; orthosteric agonist

Indexed keywords

LSP1 2111; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; DRUG CLEARANCE; DRUG PENETRATION; EXTRACELLULAR FLUID; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84894043913     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400338f     Document Type: Article

References (25)

1. Célanire, S.; Campo, B. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders Expert Opin. Drug Discovery 2012, 7, 261-280
2. Lindsley, C. W.; Hopkins, C. R. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature Expert Opin Ther. Pat. 2012, 22, 461-481
3. Beurrier, C.; Lopez, S.; Révy, D.; Selvam, C.; Goudet, C.; Lhérondel, M.; Gubellini, P.; Kerkerian-LeGoff, L.; Acher, F.; Pin, J. P.; Amalric, M. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism FASEB J. 2009, 23, 3619-3628
4. Acher, F.; Selvam, C.; Pin, J.-P. Diastereoisomers of Hypophosphorous acid derivatives. World patent application WO 2010/106526. March 19, 2010.
5. Flor, P. J.; Acher, F. C. Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs Biochem. Pharmacol. 2012, 84, 414-424
6. Goudet, A. C.; Vilar, B.; Courtiol, T.; Deltheil, T.; Bessiron, T.; Brabet, I.; Oueslati, N.; Rigault, D.; Bertrand, H.-O.; McLean, H.; Daniel, H.; Amalric, M.; Acher, F.; Pin, J.-P. A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential FASEB J. 2012, 26, 1682-1693
7. Bennouar, K. E.; Uberti, M. A.; Melon, C.; Bacolod, M. D.; Jimenez, H. N.; Cajina, M.; Kerkerian-Le Goff, L.; Doller, D.; Gubellini, P. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia Neuropharmacology 2013, 66, 158-169
8. Lopez, S.; Bonito-Oliva, A.; Pallottino, S.; Acher, F.; Fisone, G. Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease J. Parkinson's Dis. 2011, 1, 339-346
9. Wierońska, J. M.; Stachowicz, K.; Pałucha-Poniewiera, A.; Acher, F.; Brański, P.; Pilc, A. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems Neuropharmacology 2010, 59, 627-634
10. Wierońska, J. M.; Stachowicz, K.; Acher, F.; Lech, T.; Pilc, A. Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia Psychopharmacology 2012, 220, 481-494
11. 1A signalling Psychopharmacology 2013, 227, 711-725
12. Davis, M. J.; Iancu, O. D.; Acher, F. C.; Stewart, B. M.; Eiwaz M, A.; Duvoisin, R. M.; Raber, J. Role of mGluR4 in acquisition of fear learning and memory Neuropharmacology 2013, 66, 365-372
13. Green, A. R.; Gabrielsson, J.; Fone, K. C. F. Translational neuropharmacology and the appropriate and effective use of animal models Br. J. Pharmacol. 2011, 164, 1041-1043
14. Gabrielsson, J.; Green, A. R.; Van der Graaf, P. H. Optimising in vivo pharmacology studies-practical PKPD considerations J. Pharmacol. Toxicol. Methods 2010, 61, 146-156
15. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery J. Med. Chem. 2013, 56, 2-12
16. Smith, D.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
17. In silico parameters calculated using MOE (Molecular Operating system, 2012).
18. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420-434
19. Persson, M.; Løye, A. F.; Mow, T.; Hornberg, J. J. A high content screening assay to predict human drug-induced liver injury during drug discovery J. Pharmacol. Toxicol. Methods 2013, 68, 302-313
20. Broad binding counterscreen conducted at Cerep (www.cerep.com).
21. Broad functional counterscreens conducted at Euroscreen (www.euroscreen.com).
22. Cremers, T. I.; de Vries, M. G.; Huinink, K. D.; van Loon, J. P.; v d Hart, M.; Ebert, B.; Westerink, B. H.; De Lange, E. C. Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique J. Neurosci. Methods 2009, 178, 249-254
23. Rorick-Kehn, L. M.; Perkins, E. J.; Knitowski, K. M.; Hart, J. C.; Johnson, B. G.; Schoepp, D. D.; McKinzie, D. L. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344 J. Pharmacol. Exp Ther. 2006, 316, 905-13 (Pubitemid 43131021)
24. Triplett, J. W.; Hayden, T. L.; McWhorter, L. K.; Gautam, S. R.; Kim, E.; Bourne, E. D. W. A. Determination of gallium concentration in "blood-free" tissues using a radiolabeled blood marker J. Pharm. Sci. 1985, 74, 1007-1009 (Pubitemid 15014150)
25. Monn, J. A.; Massey, S. M.; Valli, M. J.; Henry, S. S.; Stephenson, G. A.; Bures, M.; Hérin, M.; Catlow, J.; Giera, D.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo- [3.1.0]hexane-4,6-dicarboxylate: Identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors J. Med. Chem. 2007, 50, 233-40 (Pubitemid 46147704)